1332 results
What did we learn from my TAVI complications?
22 May 2025 – From EuroPCR 2025
Review critical lessons from TAVI complications, focusing on early identification and management of access site issues and acute coronary obstruction. Learn effective preventive actions and procedural strategies to minimize severe TAVI-related complications through detailed case discussions.
Leaflet modification to prevent coronary obstruction during TAVI
22 May 2025 – From EuroPCR 2025
This session addresses advanced leaflet modification techniques to prevent coronary obstruction during TAVI. Learn from detailed cases involving valve-in-valve interventions, treatment of failed stentless valves, homograft management, and dedicated devices for leaflet modification prior to valve-in-valve and valve-in-valve-in-valve procedures.
TAVI - Outcomes predictors
22 May 2025 – From EuroPCR 2025
Examine novel predictors of outcomes following TAVI. This session compares a new nutritional risk index against traditional scores for early post-TAVI mortality prediction and evaluates uric acid as a marker for aortic valve calcification and mortality risk in TAVI patients.
Coronary protection during native and valve-in-valve TAVI
22 May 2025 – From EuroPCR 2025
Understand the critical role of coronary protection during native and valve-in-valve transcatheter aortic valve implantation (TAVI). This session covers procedural planning essentials, the impact of upfront coronary protection, challenges in coronary obstruction diagnosis, and the use of guide catheter extension to facilitate protection during TAVI procedures.
TAVI for aortic regurgitation off label
22 May 2025 – From EuroPCR 2025
Explore off-label applications of TAVI for aortic regurgitation in complex clinical scenarios. Topics include TAV-in-SAV with Trilogy valve for severe regurgitation, challenges of transcatheter prosthesis in pure aortic regurgitation, management of surgical valve perforations, and treatment strategies in post-surgical anatomies including degenerative homografts and aortic dissection.
Emerging indications for TAVI in 2025
22 May 2025 – From EuroPCR 2025
Prepare for emerging TAVI indications anticipated in 2025. This session reviews clinical cases including asymptomatic severe aortic stenosis, moderate aortic stenosis with heart failure, and severe aortic regurgitation. It discusses supporting evidence from clinical trials, evolving transcatheter technologies, and practical treatment approaches for these novel indications.
Redo TAVI - How to treat different TAVI platforms when they fail
22 May 2025 – From EuroPCR 2025
Understand the complexities of redo TAVI procedures with emphasis on planning, valve platform characteristics, and tailored procedural strategies. This session features cases of redo TAVI for failed short-frame and tall-frame valves, alongside discussions on current evidence gaps guiding optimal management.
TAVI in women
22 May 2025 – From EuroPCR 2025
Focus on gender-specific considerations in TAVI with this session. Topics include timely management and referral disparities in women with severe aortic stenosis, early outcomes from the LANDMARK trial with latest-generation valves, insights from NAVULTRA comparing valve types, prosthesis-patient mismatch data, and gender differences in right ventricular...
Innovations in transcatheter aortic valve devices and techniques
22 May 2025 – From EuroPCR 2025
Explore the latest advancements in transcatheter aortic valve devices and innovative procedural techniques. This session presents initial clinical experiences with new self-expandable valves in small annuli, safety and performance data from the GENESIS-II study on the Hydra valve, and up to 12-month outcomes from the Valvosoft...
China experience in TAVI evolution
22 May 2025 – From EuroPCR 2025
This session highlights key innovations and recent research from China in the field of transcatheter aortic valve implantation (TAVI). Leading cardiovascular specialist present new data on pacing strategies, comparing left bundle branch area pacing with traditional right ventricular pacing in TAVI patients. They also explore the use...
How to optimise TAVI outcomes in the Asian-Pacific population?
22 May 2025 – From EuroPCR 2025
What are the key considerations for TAVI in Asian-Pacific patients? This EuroPCR 2025 session focuses on optimising outcomes in anatomically and clinically specific contexts, such as patients with small annuli. Learn how the latest intra-annular self-expanding devices can help reduce post-procedural pacemaker implantation (PPI) rates, and...
Optimising self-expandable TAVI clinical outcomes without compromise
22 May 2025 – From EuroPCR 2025
Optimising patient outcomes in self-expandable TAVI starts with a clear plan for today, and tomorrow. This EuroPCR 2025 session explores how to make each step count, from access to implantation and closure, using a real-life case of a 77-year-old woman with severe symptomatic aortic stenosis and...
Shaping the future of cardiology - A journey of meaningful innovation in structural heart and coronary
22 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session highlights the latest device innovations reshaping interventional cardiology. Learn how the Myval OCTAPRO THV combines predictable deployment with minimal foreshortening for improved outcomes in structural heart procedures. In the coronary space, the session explores the renewed appeal of the “leave nothing behind”...
TAVI for bioprosthetic valve failure - LIVE Case
22 May 2025 – From EuroPCR 2025
A 68-year-old male patient with a history of Sapien 3 26 mm TAVI (2021), complicated by the need for two valves (one displaced in the descending aorta) and permanent pacemaker implantation, as well as endocarditis (2022), presented with symptomatic bioprosthesis failure and reduced LV function (20...
TAVI - Head-to-head comparative studies
22 May 2025 – From EuroPCR 2025
Compare head-to-head outcomes of various TAVI devices through real-world registries and meta-analyses. This session provides insights into performance differences between self-expanding and balloon-expandable valves to inform clinical decision-making.
Hotline TAVI 3: Challenging anatomical and clinical scenarios
22 May 2025 – From EuroPCR 2025
This hotline session presents challenging anatomical and clinical scenarios in TAVI, including outcomes in bicuspid aortic valve patients, chronic aortic regurgigation, comparisons of surgical versus percutaneous approaches, and real-world data on valve performance and resource utilization.
Inludes:
- Five-year outcomes from the Evolut low risk TAVR bicuspid study
- Surgical versus...
Managing difficult problems during TAVI procedures
22 May 2025 – From EuroPCR 2025
This session reviews difficult problems and complications encountered during TAVI procedures. Learn from real-world cases, expert treatment strategies, and key takeaways to enhance management and improve patient outcomes in challenging scenarios.
The impact of paravalvular leak, permanent pacemaker implantation and the planning for reinterventions on lifetime management in TAVI patients
22 May 2025 – From EuroPCR 2025
How do paravalvular leak, pacemaker implantation and reintervention planning shape lifetime outcomes in TAVI patients?
This session examines these crucial aspects through the case of a 77-year-old male with bicuspid aortic valve stenosis, HFpEF and multiple comorbidities, including diabetes, obesity and sleep apnoea.
Follow the discussion to understand...
Valve choice - Shaping index procedures and lifetime patient management
22 May 2025 – From EuroPCR 2025
This session addresses recent advancements and ongoing challenges in transcatheter aortic valve implantation (TAVI), with a particular focus on valve selection during index procedures. Presentations include data from the Accurate IDE trial, highlighting the prognostic implications of valve underexpansion. A clinical case involving an 80-year-old patient with severe...
Spotlight on major Late-Breaking Trials presented at EuroPCR 2025
21 May 2025
These trials were selected because of their design, results, and potential to impact practice: Discover the key findings of the 4D-ACS and FAITAVI randomised clinical trials and a meta-analysis of PROTECTED TAVR and BHF PROTECT TAVI.
